Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Singapore Scientists Identify New Biomarker for Cancer in Bone Marrow

Published: Friday, December 14, 2012
Last Updated: Friday, December 14, 2012
Bookmark and Share
This discovery may potentially cure patients of multiple myeloma.

Singapore scientists have identified FAIM, a molecule that typically prevents cell death, as a potential biomarker to identify an incurable form of cancer in the bone marrow.

Patients with this form of cancer usually do not get cured with current standard treatments such as chemotherapy and stem cell transplantation, with an average survival of only about four years.

FAIM could thus be a therapeutic target in these patients, as drugs developed to target the molecule could destroy multiple myeloma cells and hence eradicate the cancer.

Multiple myeloma is an incurable cancer of blood cells, which arises due to an uncontrollable accumulation of antibody-producing plasma cells in the bone marrow.

In Singapore, about 80 new cases of multiple myeloma are diagnosed every year. Unfortunately, most people who develop multiple myeloma have no clearly identifiable risk factors for the disease but factors such as individuals older than 50 years of age, men and obesity, may predispose one to the cancer.

The scientists discovered that a protein called Fas apoptosis inhibitory molecule (FAIM) can affect the activation of Akt, an important enzyme required for cancer cell proliferation.

By silencing the expression of FAIM, the team showed that the myeloma cells could be destroyed. It was also found that this protein was present at higher levels in the plasma cells of these patients as compared to normal individuals, and that higher levels of FAIM correlated to poorer survival outcomes of patients.

This is an important breakthrough as it not only identifies FAIM as a useful biomarker of multiple myeloma patients, but also as a good target that drugs can be developed for, in order to get rid of the cancer cells.

This collaborative research was conducted by scientists at A*STAR's Bioprocessing Technology Institute (BTI) led by Prof Lam Kong-Peng, along with clinician-scientists at National University Cancer Institute, Singapore (NCIS) and the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore. The research findings were published in Leukemia on 5 December 2012.

Prof Lam said, "This study adds onto previous studies in the institute demonstrating the utility of FAIM not only in biotechnology but now potentially in the clinic. It is a prime example of how a better understanding of FAIM protein function enables us to first use it to increase yield in biologics manufacturing, and now as a potential prognostic biomarker in the clinic for a deadly human disease such as multiple myeloma. This is really a translation from bench-to-bioreactor and bench-to-bedside."

"Treatment failure due to drug resistance is an important reason why patients with multiple myeloma have a poor outcome. In this study, we identified FAIM as a new biomarker that is associated with poor outcome as well as an important mediator of growth signals in myeloma cells that could lead to drug resistance. The detection of this biomarker will allow us to identify these high risk patients and possibly develop treatments that target FAIM to improve their outcome. This study also underlines the potential for collaborative work between A*STAR research institutes (BTI), CSI Singapore and the National University Cancer Institute of Singapore (NCIS) to perform research that may have significant impact on patients," said Associate Professor Chng Wee Joo, who is Senior Consultant Haematologist at the Department of Haematology-Oncology, NCIS and Senior Principal Investigator at CSI.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Colorful Nanoprobes Make A Simple Test
Gold nanoparticles linked to single-stranded DNA create a simple but versatile genetic testing kit.
Thursday, September 25, 2014
A*STAR Scientists Discover Potential Drug for Deadly Brain Cancer
This discovery can potentially prevent the progression and relapse of deadly brain tumours.
Tuesday, January 15, 2013
Breakthroughs in Chikungunya Research Spell New Hope for Better Treatment and Protection
A*STAR's SIgN have made great strides in the battle against the infectious disease.
Monday, September 24, 2012
A*STAR Scientists Pinpoint Genetic Changes that Spell Cancer
Fruit flies light the way for scientists to uncover genetic changes.
Thursday, August 16, 2012
Discovery of the Cellular Origin of Cervical Cancer
A team of scientists have identified a unique set of cells in the cervix that are the cause of HPV related cervical cancers.
Tuesday, June 12, 2012
Scientific News
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Promise of Newborn Stem Cells to Revolutionize Clinical Practice
In this article Shweta Sharma, PhD, discusses the potential of an Umbilical Cord Blood bank as an untapped source of samples for research and clinical trials.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Coronavirus Breakthrough
Protein mutation affects spread and virulence of respiratory virus.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Circadian Clock Controls Insulin and Blood Sugar in Pancreas
Map of thousands of genes suggests new therapeutic targets for diabetes.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos